CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 3)

Average Co-Inventor Count = 3.3

ph-index = 8

Forward Citations = 282(Granted Patents)

Location History:

Rahway, NJ (US) (1991 - 2003)
Plainfield, NJ (US) (2009 - 2014)

Company Filing History:

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 1991-2014

Loading Chart...

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8722727 - Antifungal agents (2014-05-13),

2. 8188085 - Antifungal agents (2012-05-29),

3. 7923568 - Estrogen receptor modulators (2011-04-12),

4. 7863465 - Antifungal agents (2011-01-04),

5. 7745657 - D-homoandrosta-17-yl carbamate derivatives as selective glucocorticoid receptor ligands (2010-06-29),

6. 7732432 - 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators (2010-06-08),

7. 7709508 - Estrogen receptor modulators (2010-05-04),

8. 7511152 - Estrogen receptor modulators (2009-03-31),

9. 6630510 - Substituted succinic acid metallo-&bgr;-lactamase inhibitors and their use in treating bacterial infections (2003-10-07),

10. 5451579 - 1-.beta.-methyl-carbapenem, compositions containing same and methods of (1995-09-19),

11. 5395931 - 6-amido-1-methyl-2-(substituted-thio)carbapenems (1995-03-07),

12. 5356889 - 2-(9-fluorenonyl)-carbapenem intermediates (1994-10-18),

13. 5336674 - 2-phenanthridinyl carbaphenem antibacterial agent (1994-08-09),

14. 5328904 - 2-phenanthridinyl carbapenem antibacterial agents (1994-07-12),

15. 5240920 - 2-(substituted-dibenzofuranyl and dibenzothienyl) carbapenem (1993-08-31),

Title: Celebrating the Innovation of Mark L Greenlee: A Leader in Antifungal Research

Introduction: Mark L Greenlee, based in Rahway, NJ, is a prolific inventor with an impressive portfolio of 39 patents. His contributions to pharmaceutical science, particularly in developing antifungal agents, have made significant impacts in the field.

Latest Patents: Among his latest innovations are novel derivatives of enfumafungin, which are disclosed along with their pharmaceutically acceptable salts, hydrates, and prodrugs. These compounds are crucial for developing effective treatments against fungal infections. His patents detail compositions comprising these compounds and methods for their preparation and application as antifungal agents and/or inhibitors of (1,3)-β-D-glucan synthase. The implications of these compounds extend to treating and preventing various fungal infections and related diseases, showcasing his commitment to advancing medical science.

Career Highlights: Mark Greenlee's career spans reputable institutions such as Merck & Company, Inc. and Merck Sharp & Dohme Corporation. His work at these companies underscored his expertise and dedication to innovative pharmaceutical development, particularly regarding formulations that enhance efficacy in combating fungal diseases.

Collaborations: Throughout his career, Greenlee has collaborated with distinguished professionals in the field, including Frank P DiNinno and Thomas N Salzmann. These partnerships have fostered a collaborative environment conducive to innovation and excellence in research and development.

Conclusion: Mark L Greenlee’s contributions to antifungal research through his numerous patents and collaborations reflect his unwavering dedication to improving healthcare outcomes. His innovative approaches continue to influence the landscape of pharmaceutical sciences, highlighting the essential role of inventors in advancing medical technologies.

This text is generated by artificial intelligence and may not be accurate.